title: Roundtable discussion: Part II--Development of a pharmacoeconomic model in hypertension.
abstract: Antihypertensive medications are targeted by most health plans as a major cost center. However, the efficacy of these medications, their side effects, and their resulting ability to prevent serious long-term complications must be factored into the value equation. To illustrate the possible economic effects of a single antihypertensive agent's inclusion on a health plan's drug formulary, an innovative pharmacoeconomic model was developed. In this portion of the roundtable, the design, results, and caveats of this model are discussed.
authors.forename: P
authors.initials: P
authors.lastname: Penna
authors.forename: E
authors.initials: E
authors.lastname: Cox
authors.forename: T
authors.initials: T
authors.lastname: Joseph
authors.forename: L
authors.initials: L
authors.lastname: Lehman
authors.forename: T
authors.initials: T
authors.lastname: Morrow
authors.forename: A
authors.initials: A
authors.lastname: Richter
authors.forename: J
authors.initials: J
authors.lastname: Sowers
authors.forename: D
authors.initials: D
authors.lastname: Tepper
mesh_terms: D000959:Antihypertensive Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use; D004363:Drug Utilization / Q000191:economics; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000191:economics; D017059:Models, Econometric; D010818:Practice Patterns, Physicians'; D016896:Treatment Outcome; D014481:United States
chemical_list: D000959:Antihypertensive Agents